Tags

Type your tag names separated by a space and hit enter

Treatment of irritable bowel syndrome. A case control experience.
Minerva Gastroenterol Dietol. 2006 Dec; 52(4):359-63.MG

Abstract

AIM

As optimal therapy for irritable bowel syndrome (IBS) remains elusive, current approach to therapy is based on symptomatic treatment. With this case-control experience we wanted to determine the beneficial effect in IBS patients of a dietary integrator (IBS Active), composed of L-tryptophan, inulin, angelica, vegetal charcoal, vitamin PP, group B vitamins (B1, B2, B6) and probiotics (Lactobacillus sporogenes, Lactobacillus acidophilus, Streptococcus thermophilus).

METHODS

The treatment group comprised 37 patients (11 men and 27 women; mean age, 44.3+/-5.1 years) given IBS Active (440 mg bid) over a mean period of 6 months (range, 5-8). The control group comprised 28 patients (6 men and 22 women; mean age, 48.6+/-3.7 years) who were instructed to continue their customary therapy for 6 months (range, 5-7). All subjects were assessed for the presence of abdominal pain and/or distension, constipation, diarrhea and alternating constipation and diarrhea.

RESULTS

Compared with baseline values, the reduction in abdominal pain in the treatment group was 62% (P<0.0001), 55% (P<0.0001) in abdominal distension, 58% (P=0.05) in constipation, 33% (P=0.3) in diarrhea, and 62% (P=0.01) in alternation constipation and diarrhea. Compared with baseline values, no statistically significant reduction in symptoms was found in the control group. Post-treatment comparison between the two groups showed that the study product had reduced symptoms and that the difference was statistically significant for abdominal pain (P<0.000001), abdominal distension (P=0.003) and constipation (P=0.03).

CONCLUSIONS

The use of IBS Active led to a significant improvement in pain symptoms, abdominal distension and regulation of bowel movement in IBS patients. Further study is needed to evaluate the long-term benefit of the study product.

Authors+Show Affiliations

Department of Gastroenterology and Hepatology, San Giovanni Battista (Molinette) Hospital, Turin, Italy. mastegiano@molinette.piemonte.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

17108865

Citation

Astegiano, M, et al. "Treatment of Irritable Bowel Syndrome. a Case Control Experience." Minerva Gastroenterologica E Dietologica, vol. 52, no. 4, 2006, pp. 359-63.
Astegiano M, Pellicano R, Terzi E, et al. Treatment of irritable bowel syndrome. A case control experience. Minerva Gastroenterol Dietol. 2006;52(4):359-63.
Astegiano, M., Pellicano, R., Terzi, E., Simondi, D., & Rizzetto, M. (2006). Treatment of irritable bowel syndrome. A case control experience. Minerva Gastroenterologica E Dietologica, 52(4), 359-63.
Astegiano M, et al. Treatment of Irritable Bowel Syndrome. a Case Control Experience. Minerva Gastroenterol Dietol. 2006;52(4):359-63. PubMed PMID: 17108865.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of irritable bowel syndrome. A case control experience. AU - Astegiano,M, AU - Pellicano,R, AU - Terzi,E, AU - Simondi,D, AU - Rizzetto,M, PY - 2006/11/17/pubmed PY - 2007/3/16/medline PY - 2006/11/17/entrez SP - 359 EP - 63 JF - Minerva gastroenterologica e dietologica JO - Minerva Gastroenterol Dietol VL - 52 IS - 4 N2 - AIM: As optimal therapy for irritable bowel syndrome (IBS) remains elusive, current approach to therapy is based on symptomatic treatment. With this case-control experience we wanted to determine the beneficial effect in IBS patients of a dietary integrator (IBS Active), composed of L-tryptophan, inulin, angelica, vegetal charcoal, vitamin PP, group B vitamins (B1, B2, B6) and probiotics (Lactobacillus sporogenes, Lactobacillus acidophilus, Streptococcus thermophilus). METHODS: The treatment group comprised 37 patients (11 men and 27 women; mean age, 44.3+/-5.1 years) given IBS Active (440 mg bid) over a mean period of 6 months (range, 5-8). The control group comprised 28 patients (6 men and 22 women; mean age, 48.6+/-3.7 years) who were instructed to continue their customary therapy for 6 months (range, 5-7). All subjects were assessed for the presence of abdominal pain and/or distension, constipation, diarrhea and alternating constipation and diarrhea. RESULTS: Compared with baseline values, the reduction in abdominal pain in the treatment group was 62% (P<0.0001), 55% (P<0.0001) in abdominal distension, 58% (P=0.05) in constipation, 33% (P=0.3) in diarrhea, and 62% (P=0.01) in alternation constipation and diarrhea. Compared with baseline values, no statistically significant reduction in symptoms was found in the control group. Post-treatment comparison between the two groups showed that the study product had reduced symptoms and that the difference was statistically significant for abdominal pain (P<0.000001), abdominal distension (P=0.003) and constipation (P=0.03). CONCLUSIONS: The use of IBS Active led to a significant improvement in pain symptoms, abdominal distension and regulation of bowel movement in IBS patients. Further study is needed to evaluate the long-term benefit of the study product. SN - 1121-421X UR - https://www.unboundmedicine.com/medline/citation/17108865/Treatment_of_irritable_bowel_syndrome__A_case_control_experience_ L2 - http://www.diseaseinfosearch.org/result/3876 DB - PRIME DP - Unbound Medicine ER -